Loading...
XKRX090370
Market cap22mUSD
Dec 26, Last price  
1,322.00KRW
1D
0.00%
1Q
-19.02%
Jan 2017
-93.67%
IPO
-99.42%
Name

MetaLabs Co Ltd

Chart & Performance

D1W1MN
XKRX:090370 chart
P/E
—
P/S
1.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.10%
Rev. gr., 5y
-14.54%
Revenues
21.60b
-4.68%
96,691,754,000115,633,244,000127,014,045,000124,493,331,000151,702,804,810145,623,074,000141,412,155,020127,864,761,590115,996,783,08092,066,961,94026,832,431,61047,375,133,98086,896,351,29083,353,809,65039,300,730,76022,659,042,21021,598,887,650
Net income
-7.30b
L-43.03%
11,167,976,0001,701,550,000-4,123,168,000-2,350,432,000478,478,000-26,417,144,000-11,079,980,270-4,037,119,140-36,710,092,120-39,219,756,780-37,939,377,530-13,521,275,940-25,362,334,390-19,340,233,270-16,200,774,560-12,812,632,080-7,299,953,580
CFO
-50m
L
-1,559,379,000-335,133,000-13,404,655,0002,222,974,000-4,021,706,910-8,870,478,8002,567,033,290-10,838,135,350-7,883,383,220-10,014,767,330-8,468,021,080-6,896,735,860-4,021,331,0201,363,610,6202,279,490,380447,640,150-49,571,895
Dividend
Dec 27, 201227.309 KRW/sh
Earnings
Feb 14, 2025

Profile

Metalabs Co., Ltd. primarily provides clothing in South Korea. It also manufactures and distributes prescription drugs, medical devices, and masks; develops peptide-based bio products; offers medical management services; and distributes cosmetics, as well as operates dating applications. The company was formerly known as Avista Inc. and changed its name to Metalabs Co., Ltd. in April 2018. Metalabs Co., Ltd. was founded in 2000 and is based in Seoul, South Korea.
URL
http://www.metalabs.co.kr/
IPO date
Dec 26, 2006
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
21,598,888
-4.68%
22,659,042
-42.34%
39,300,731
-52.85%
Cost of revenue
20,989,081
17,247,553
30,569,035
Unusual Expense (Income)
NOPBT
609,806
5,411,489
8,731,696
NOPBT Margin
2.82%
23.88%
22.22%
Operating Taxes
(502,185)
(844,081)
(669,046)
Tax Rate
NOPAT
1,111,991
6,255,570
9,400,741
Net income
(7,299,954)
-43.03%
(12,812,632)
-20.91%
(16,200,775)
-16.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,991,954
5,999,999
BB yield
-53.87%
-8.14%
Debt
Debt current
4,601,762
4,634,901
11,325,671
Long-term debt
27,905,697
2,372,574
2,832,505
Deferred revenue
151,773
Other long-term liabilities
2,142,907
397,029
(250)
Net debt
(51,438,768)
(39,516,877)
(3,557,651)
Cash flow
Cash from operating activities
(49,572)
447,640
2,279,490
CAPEX
(38,809,674)
(2,571,935)
(409,831)
Cash from investing activities
(27,254,926)
(27,950,546)
(20,699,546)
Cash from financing activities
26,934,004
18,340,992
26,289,673
FCF
2,526,697
(652,549)
26,929,986
Balance
Cash
1,719,136
17,139,629
20,792,675
Long term investments
82,227,091
29,384,723
(3,076,849)
Excess cash
82,866,283
45,391,400
15,750,790
Stockholders' equity
60,707,449
58,363,919
25,786,331
Invested Capital
46,473,879
38,865,877
52,074,466
ROIC
2.61%
13.76%
15.68%
ROCE
0.56%
6.33%
12.40%
EV
Common stock shares outstanding
24,902
22,769
15,693
Price
2,225.00
-9.00%
2,445.00
-47.92%
4,695.00
-12.24%
Market cap
55,406,125
-0.47%
55,670,369
-24.44%
73,678,475
17.74%
EV
5,527,734
16,362,279
74,528,704
EBITDA
2,960,179
8,496,234
12,356,851
EV/EBITDA
1.87
1.93
6.03
Interest
812,098
2,098,727
990,356
Interest/NOPBT
133.17%
38.78%
11.34%